Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsNA

The Effect of Short-term Supplementation of OliPhenolia® on Fat Oxidation

Sponsor: Anglia Ruskin University

NCT ID: NCT07210099

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Concentrated olive fruit water (supplement), Placebo (supplement), Anhydrous caffeine (supplement), Placebo beverage (supplement)
How long the study runs
Study runs about 16 months (dates as stated)
About the drug or intervention
Concentrated olive fruit water — supplement: Supplementation of OliPhenolia twice daily for eight days. · Placebo — supplement: Placebo matched for taste and appearance consumed twice daily for eight days in the equivalent volume to the experimental product. · Anhydrous caffeine — supplement: A single bolus of flavoured water (150mL) containing 6mg/kg anhydrous caffeine taken as a pre-exercise beverage · Placebo beverage — supplement: A single bolus of flavoured water (150mL) containing 6mg/kg microcrystalline cellulose
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
21 Years and over
Who
All
Number of participants
40
Started
2025-05-30
Last checked
2026-03

Plain English Summary

What is this study?

  • • Testing a new treatment for healthy
  • • NA - 40 participants
  • • There is current research interest in the use of fruit and plant-based food products containing high levels of natural antioxidants and their impact on exercise, which may be particularly beneficial for recreationally or low-active populations

Who can take part?

  • • Ages 21 Years and over
  • • Diagnosed with healthy

Where?

  • • Cambridge - Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University,

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

There is current research interest in the use of fruit and plant-based food products containing high levels of natural antioxidants and their impact on exercise, which may be particularly beneficial for recreationally or low-active populations. One such product is an olive extract drink (called OliPhenolia®) produced by Fattoria La Vialla (an organic farm based in Northern Italy) and commercially available for the general public. Whilst previous research from the investigators (at Anglia Ruskin University) using this product has demonstrated potential antioxidant benefits and reduced oxygen cost during aerobic exercise, there are to date no studies investigating whether the short-term consumption of OliPhenolia® can benefit fat oxidation during exercise or whether such effects can be further enhanced employing a pre workout caffeinated beverage. Therefore the aim of this study is two-fold: i) to assess the impact of short-term supplementation (8 days) of OliPhenolia® relative to body mass on fat oxidation during aerobic cycling exercise in comparison to placebo in healthy recreationally active volunteers; and ii) whether potential benefits of OliPhenolia® on fat oxidation are enhanced with a pre-workout caffeinated beverage in comparison to placebo in healthy recreationally active volunteers.

More detail

This exploratory study will involve initial recruitment of approximately 30-40 healthy volunteers to undertake an initial study briefing pre-screening health questionnaire, informed written consent and familiarisation to exercise equipment, before returning to the human physiology laboratory at Anglia Ruskin University on a separate occasion (Visit 1) to undertake a standard exercise test for maximal fitness capacity. Following this, Visit 2 will see participants undertake a standard fat oxidation exercise test (aerobic exercise on a cycle ergometer) to ascertain maximal fat oxidation (Fatmax) with increasing exercise intensity, as well as a steady state exercise bout (30mins at FATmax). After this participants will begin a short-term (8 days) supplementation period of either OliPhenolia or Placebo before returning for a follow up fat oxidation assessment (Visit 3) as above. Fat oxidation will be assessed by standard respiratory measures (breath to breath for oxygen and carbon dioxide). On the follow up test (Visit 3), a pre-exercise workout drink will be provided containing either caffeine flavoured water or placebo. This is to assess whether fat oxidation can be enhanced from short-term polyphenol supplementation (OliPhenolia) with or without additional caffeine prior to exercise. Participants will therefore be randomised into 1 of 4 groups for this study (Placebo product for 8 days + placebo beverage at follow up; Oliphenolia for 8 days + placebo beverage at follow up; and OliPhenolia for 8 days plus caffeinated beverage at follow up; and placebo product for 8 days plus caffeinated beverage at follow up).

Healthy

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 21 Years and over
  • Who can join: All genders

Biomarkers mentioned

met

What the study is looking for

  • ✓Men and women, UK based, above 21 years of age with a body mass index (BMI) \>18 and \<30 kg·m2 determined during...
  • ✓No known history (including family history) of heart abnormalities, hypertension, coronary heart disease or diabetes...
  • ✓Not currently suffering from any musculoskeletal injury, or any other reason that may prevent participation in...
  • ✓Have not suffered from recent viral infections ie: influenza (defined within the prior 2 months).
  • ✓Not taking any prescribed or over-the-counter medication which may influence exercise training (with the exception...

Who cannot take part

  • ✗If any of the above criteria is not met.
See the full criteria
Inclusion Criteria: * Men and women, UK based, above 21 years of age with a body mass index (BMI) \>18 and \<30 kg·m2 determined during baseline testing * Considered to be recreationally active i.e. approximately 150mins of general physical activity/ exercise per week (meeting the WHO physical activity guidelines); and a VO2peak (fitness) score \>20 and \<50 mL·kg-1·min-1 determined during baseline testing. * No known history (including family history) of heart abnormalities, hypertension, coronary heart disease or diabetes (determined from pre-study health screen questionnaire). * Not currently suffering from any musculoskeletal injury, or any other reason that may prevent participation in cardiovascular exercise. * Have not suffered from recent viral infections ie: influenza (defined within the prior 2 months). * Not taking any prescribed or over-the-counter medication which may influence exercise training (with the exception of inhalers for exercise induced asthma or contraceptive pill). * Not consuming or prepared to refrain from consumption, any commercial supplementation which conflicts with the study parameters ie: antioxidants. * No known allergy or intolerance to olives or prune/grape juice, or any known side effects from caffeine ingestion. Exclusion Criteria: * If any of the above criteria is not met.

Where Is This Study? (1 UK site)

Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University,

Cambridge CB1 1PT, United Kingdom

Recruiting
Site contact (verified)
Justin D Roberts, PhDPrincipal Investigator

How to Get in Touch

Justin D Roberts, Professor

Sponsor contact

CONTACT

07794122020 justin.roberts@aru.ac.uk

Joseph B Lillis

Sponsor contact

CONTACT

07713870153 JBL115@pgr.aru.ac.uk
Data sourced from ClinicalTrials.gov · Last verified: 2026-03